CUMULATIVE SUPPLEMENT 1
JANUARY 2020



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

Cumulative Supplement 1
January 2020

CONTENTS

PAGE

Contents

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

CUMULATIVE SUPPLEMENT 1
JANUARY 2020

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP	0.3MG	N021116	RLD	–

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[2] Please consult the Active Section of the Orange Book for information on other strengths.

		LLC				
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2019	MAR 2020	JUN 2020	SEP 2020	DEC 2020
DRUG PRODUCTS	20567				
LISTED SINGLE SOURCE	2743 (13.3%)				
MULTISOURCE	17824 (86.7%)				

THERAPEUTICALLY EQUIVALENT	17740 (86.3%)
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)
EXCEPTIONS[4]	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	17
NUMBER OF APPLICANTS	1162

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).

[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA		XIROMED	325MG;5MG	A211690	001	Feb 07, 2020	Jan NEWA
>A>	AA			325MG;7.5MG	A211690	002	Feb 07, 2020	Jan NEWA
>A>	AA			325MG;10MG	A211690	003	Feb 07, 2020	Jan NEWA

ACYCLOVIR

CREAM;TOPICAL

ACYCLOVIR

>D>	AB		PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan CHRS
>A>	AB	!		5%	A208702	001	Feb 04, 2019	Jan CHRS

ZOVIRAX

>D>	AB	+!	BAUSCH	5%	N021478	001	Dec 30, 2002	Jan CHRS
>A>	AB	+		5%	N021478	001	Dec 30, 2002	Jan CHRS

OINTMENT;TOPICAL

ACYCLOVIR

>A>	AB		XIROMED	5%	A201501	001	Jan 29, 2020	Jan NEWA

TABLET;ORAL

ACYCLOVIR

>D>	AB		HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan CHRS
>A>	AB	!		800MG	A203834	002	Oct 29, 2013	Jan CHRS
>D>			ZOVIRAX					
>D>	AB	+	MYLAN	400MG	N020089	001	Apr 30, 1991	Jan DISC
>A>		+ @		400MG	N020089	001	Apr 30, 1991	Jan DISC
>D>	AB	+!		800MG	N020089	002	Apr 30, 1991	Jan DISC
>A>		+ @		800MG	N020089	002	Apr 30, 1991	Jan DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

>D>		+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan CHRS
>A>		+!		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan CHRS

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	AB		SANDOZ	10MG	A085968	004		Jan CMS1
>A>	AB	!		25MG	A085968	002		Jan CMS1
>A>	AB			75MG	A085968	006		Jan CMS1
>A>	AB			100MG	A085968	003		Jan CMS1
>A>	AB			150MG	A085968	005		Jan CMS1

AMOXAPINE

TABLET;ORAL

AMOXAPINE

>D>			@ WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Jan CMS1
>A>			@	25MG	A072418	001	Aug 01, 1989	Jan CMS1
>D>			@	50MG	A072419	001	May 11, 1989	Jan CMS1
>A>			@	50MG	A072419	001	Aug 01, 1989	Jan CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB		AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan CAHN
>D>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan CAHN
>D>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan CAHN
>D>	AB			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan CAHN
>D>	AB			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan CAHN
>D>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan CAHN
>A>	AB		ANI PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan CAHN
>A>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan CAHN
>A>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan CAHN
>A>	AB			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan CAHN
>A>	AB			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan CAHN
>A>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan CAHN

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jan	DISC
>A>		@	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jan	DISC
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jan	DISC
>A>		@	2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jan	DISC
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jan	DISC
>A>		@	3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jan	DISC
>D>	AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jan	DISC
>A>		@	5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jan	DISC
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jan	DISC
>A>		@	6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jan	DISC
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jan	DISC
>A>		@	7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jan	DISC

AMPHETAMINE SULFATE

TABLET;ORAL
AMPHETAMINE SULFATE

>A>	AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA
>A>	AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION
AMPICILLIN AND SULBACTAM

>D>		@ MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan	CAHN
>D>		@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan	CAHN
>A>		@ PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan	CAHN
>A>		@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan	CAHN

ANASTROZOLE

TABLET;ORAL
ANASTROZOLE

>D>	AB	MYLAN	1MG	A091051	001	Jun 28, 2010	Jan	DISC
>A>		@	1MG	A091051	001	Jun 28, 2010	Jan	DISC

APIXABAN

TABLET;ORAL
APIXABAN

>D>	AB	MYLAN	2.5MG	A210128	001	Dec 23, 2019	Jan	DISC
>A>		@	2.5MG	A210128	001	Dec 23, 2019	Jan	DISC
>D>	AB		5MG	A210128	002	Dec 23, 2019	Jan	DISC
>A>		@	5MG	A210128	002	Dec 23, 2019	Jan	DISC

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

>D>		+ ALLERGAN	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Jan	CMS1
>A>		+	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan	CMS1

ATORVASTATIN CALCIUM

TABLET;ORAL
ATORVASTATIN CALCIUM

>D>		@ LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan	CMFD
>A>	AB		EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan	CMFD
>D>		@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan	CMFD
>A>	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan	CMFD
>D>		@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan	CMFD
>A>	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan	CMFD
>D>		@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan	CMFD
>A>	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan	CMFD

>A> AVAPRITINIB

>A> TABLET;ORAL
>A> AYVAKIT

>A>		+ BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan	NEWA
>A>		+	200MG	N212608	002	Jan 09, 2020	Jan	NEWA
>A>		+!	300MG	N212608	003	Jan 09, 2020	Jan	NEWA

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

>A>	AB		ALEMBIC PHARMS LTD	EQ 250MG BASE	A211791	001	Jan 28, 2020	Jan NEWA
>A>	AB			EQ 500MG BASE	A211792	001	Jan 28, 2020	Jan NEWA
>A>	AB			EQ 600MG BASE	A211793	001	Jan 27, 2020	Jan NEWA
>D>	AB		MYLAN	EQ 600MG BASE	A065360	001	Jan 08, 2007	Jan DISC
>A>		@		EQ 600MG BASE	A065360	001	Jan 08, 2007	Jan DISC

BACLOFEN

TABLET;ORAL

BACLOFEN

>D>	AB		MYLAN	20MG	A077121	002	Jul 29, 2005	Jan DISC
>A>		@		20MG	A077121	002	Jul 29, 2005	Jan DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

>D>	AA		AMNEAL PHARM	5MG	A040855	001	Nov 21, 2007	Jan CHRS
>A>	AA	!		5MG	A040855	001	Nov 21, 2007	Jan CHRS
>D>	AA			10MG	A040855	002	Nov 21, 2007	Jan CHRS
>A>	AA	!		10MG	A040855	002	Nov 21, 2007	Jan CHRS
>D>	AA			25MG	A040855	003	Nov 21, 2007	Jan CHRS
>A>	AA	!		25MG	A040855	003	Nov 21, 2007	Jan CHRS
>D>		@	IMPAX LABS	25MG	A040721	003	Nov 01, 2016	Jan CMS1
>A>		@		25MG	A040721	003	Nov 01, 2006	Jan CMS1

URECHOLINE

>D>	AA	!	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985	Jan DISC
>A>		@		5MG	A089095	001	Dec 19, 1985	Jan DISC
>D>	AA	!		10MG	A088440	001	May 29, 1984	Jan DISC
>A>		@		10MG	A088440	001	May 29, 1984	Jan DISC
>D>	AA	!		25MG	A088441	001	May 29, 1984	Jan DISC
>A>		@		25MG	A088441	001	May 29, 1984	Jan DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

>D>	AB		AMERIGEN PHARMS LTD	75MG	A209861	001	May 08, 2018	Jan CAHN
>A>	AB		ANI PHARMS INC	75MG	A209861	001	May 08, 2018	Jan CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

>D>	AB		MYLAN	50MG	A079185	001	Jul 06, 2009	Jan DISC
>A>		@		50MG	A079185	001	Jul 06, 2009	Jan DISC

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

>A>	AT		ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan NEWA

BOSENTAN

TABLET;ORAL

BOSENTAN

>A>	AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan NEWA
>A>	AB			125MG	A211461	002	Jan 23, 2020	Jan NEWA
>D>	AB		MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan DISC
>A>		@		62.5MG	A205173	001	Jan 15, 2020	Jan DISC
>D>	AB			125MG	A205173	002	Jan 15, 2020	Jan DISC
>A>		@		125MG	A205173	002	Jan 15, 2020	Jan DISC

BUMETANIDE

TABLET;ORAL

BUMETANIDE

>D>	AB		CEYONE	0.5MG	A212019	001	Dec 12, 2019	Jan CAHN
>D>	AB			1MG	A212019	002	Dec 12, 2019	Jan CAHN
>D>	AB			2MG	A212019	003	Dec 12, 2019	Jan CAHN
>A>	AB		RISING	0.5MG	A212019	001	Dec 12, 2019	Jan CAHN
>A>	AB			1MG	A212019	002	Dec 12, 2019	Jan CAHN
>A>	AB			2MG	A212019	003	Dec 12, 2019	Jan CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB		CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan NEWA
>A>	AB			100MG	A208606	002	Jan 16, 2020	Jan NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

>D>		+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jan CAHN
>A>		+!		90MG;8MG	N200063	001	Sep 10, 2014	Jan CAHN

CABERGOLINE

TABLET;ORAL

CABERGOLINE

>D>	AB		MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan DISC
>A>		@		0.5MG	A202947	001	Dec 02, 2013	Jan DISC

CALCITRIOL

INJECTABLE;INJECTION

CALCITRIOL

>D>		!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
>A>	AP	!		0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
>A>	AP		GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>D>	AB		LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan DISC
>A>		@		667MG	A203298	001	Jul 26, 2016	Jan DISC

CARBIDOPA

TABLET;ORAL

CARBIDOPA

>D>	AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Jan CAHN
>A>	AB		ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan CAHN

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

>D> SINEMET CR

>D>	AB	+	MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan DISC
>A>		+ @		25MG;100MG	N019856	002	Dec 24, 1992	Jan DISC

CEFIXIME

FOR SUSPENSION;ORAL

SUPRAX

>D>	AB		LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan DISC
>A>		@		100MG/5ML	A065129	001	Feb 23, 2004	Jan DISC

TABLET;ORAL

SUPRAX

>D>		!	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan DISC
>A>		@		400MG	A065130	001	Feb 12, 2004	Jan DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

>D>	AP		HOSPIRA INC	EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan DISC
>A>		@		EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan DISC

CELECOXIB

>A> CAPSULE;ORAL

>A> CELECOXIB

>A>	AB		UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan CDFR
>A>	AB			100MG	A210628	002	Nov 27, 2019	Jan CDFR
>A>	AB			200MG	A210628	003	Nov 27, 2019	Jan CDFR
>A>	AB			400MG	A210628	004	Nov 27, 2019	Jan CDFR

>D> TABLET;ORAL

>D> CELECOXIB

>D>	AB		UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan CDFR
>D>	AB			100MG	A210628	002	Nov 27, 2019	Jan CDFR
>D>	AB			200MG	A210628	003	Nov 27, 2019	Jan CDFR

>D>		TABLET;ORAL						
>D>		CELECOXIB						
>D>	AB		400MG	A210628	004	Nov 27, 2019	Jan	CDFR
		CHLORPROMAZINE HYDROCHLORIDE						
		TABLET;ORAL						
		CHLORPROMAZINE HYDROCHLORIDE						
>A>	AB	ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan	NEWA
>A>	AB		25MG	A213368	002	Jan 17, 2020	Jan	NEWA
>A>	AB		50MG	A213368	003	Jan 17, 2020	Jan	NEWA
>A>	AB		100MG	A213368	004	Jan 17, 2020	Jan	NEWA
>A>	AB		200MG	A213368	005	Jan 17, 2020	Jan	NEWA
		CHLORTHALIDONE						
		TABLET;ORAL						
		CHLORTHALIDONE						
>A>	AB	ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan	NEWA
>A>	AB		50MG	A213412	002	Feb 11, 2020	Jan	NEWA
		CHOLESTYRAMINE						
		POWDER;ORAL						
		LOCHOLEST						
>A>		@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan	CAHN
>A>		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan	CAHN
>D>		@ SANDOZ	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan	CAHN
>D>		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan	CAHN
		CINACALCET HYDROCHLORIDE						
		TABLET;ORAL						
		CINACALCET HYDROCHLORIDE						
>D>	AB	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan	DISC
>A>		@	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan	DISC
>D>	AB		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan	DISC
>A>		@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan	DISC
>D>	AB		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan	DISC
>A>		@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan	DISC
		CISATRACURIUM BESYLATE						
		INJECTABLE;INJECTION						
		CISATRACURIUM BESYLATE						
>D>		@ HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan	CMFD
>A>	AP		EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan	CMFD
		CLOBAZAM						
		SUSPENSION;ORAL						
		CLOBAZAM						
>A>	AB	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Jan	NEWA
		CLOBETASOL PROPIONATE						
		CREAM;TOPICAL						
		CLOBETASOL PROPIONATE						
>A>	AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan	NEWA
		SPRAY;TOPICAL						
		CLOBETASOL PROPIONATE						
>D>	AT	ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Jan	DISC
>A>		@	0.05%	A211191	001	Oct 02, 2019	Jan	DISC
		CLOMIPRAMINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		CLOMIPRAMINE HYDROCHLORIDE						
>A>	AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan	NEWA
>A>	AB		50MG	A211364	002	Feb 07, 2020	Jan	NEWA
>A>	AB		75MG	A211364	003	Feb 07, 2020	Jan	NEWA
>D>		@ MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan	CMFD
>A>	AB		25MG	A211767	001	Apr 08, 2019	Jan	CMFD
>D>		@	50MG	A211767	002	Apr 08, 2019	Jan	CMFD
>A>	AB		50MG	A211767	002	Apr 08, 2019	Jan	CMFD
>D>		@	75MG	A211767	003	Apr 08, 2019	Jan	CMFD
>A>	AB		75MG	A211767	003	Apr 08, 2019	Jan	CMFD

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

>A>		NUMBRINO						
>A>		CODY LABS INC	4%	N209575	001	Jan 10, 2020	Jan	NEWA

COLCHICINE

TABLET;ORAL

		COLCHICINE						
>D>		@ AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan	CMFD
>A>	AB		0.6MG	A204711	001	Sep 28, 2016	Jan	CMFD
>A>	AB	GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan	NEWA

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

		CYCLOPHOSPHAMIDE						
>D>	AB	AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Jan	CAHN
>D>	AB		50MG	A207014	002	Mar 19, 2018	Jan	CAHN
>A>	AB	ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan	CAHN
>A>	AB		50MG	A207014	002	Mar 19, 2018	Jan	CAHN

DEFERASIROX

TABLET;ORAL

		DEFERASIROX						
>A>	AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA
>A>	AB		360MG	A211852	002	Feb 11, 2020	Jan	NEWA

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

		IPRIVASK						
>A>		+ @ BAUSCH	15MG/VIAL	N021271	001	Apr 04, 2003	Jan	CAHN
>D>		+ @ VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	Jan	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

>A>		DEXMEDETOMIDINE						
>A>	AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA
		DEXMEDETOMIDINE HYDROCHLORIDE						
>A>	AP	HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA
>A>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA
>D>	AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

		DEXTROAMPHETAMINE SULFATE						
>D>	AB	PII	5MG	A205077	001	Jun 21, 2019	Jan	DISC
>A>		@	5MG	A205077	001	Jun 21, 2019	Jan	DISC
>D>	AB		10MG	A205077	002	Jun 21, 2019	Jan	DISC
>A>		@	10MG	A205077	002	Jun 21, 2019	Jan	DISC
>D>	AB		15MG	A205077	003	Jun 21, 2019	Jan	DISC
>A>		@	15MG	A205077	003	Jun 21, 2019	Jan	DISC

DIAZEPAM

>A>		SPRAY;NASAL						
>A>		VALTOCO						
>A>		+ NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA
>A>		+	7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA
>A>		+!	10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA

DICLOFENAC POTASSIUM

TABLET;ORAL

		CATAFLAM						
>D>		@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD
>A>		+ @	50MG	N020142	002	Nov 24, 1993	Jan	CRLD

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>A>	AB		ENCUBE	1%	A210986	001	Jan 27, 2020	Jan NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

>D>	AB		MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan DISC
>A>		@		EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan DISC

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

>D>	AB		MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan DISC
>A>		@		EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan DISC
>D>	AB			EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan DISC
>A>		@		EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan DISC
>D>	AB			EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan DISC
>A>		@		EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan DISC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>D>		@	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan CMFD
>A>	AP			20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan CMFD
>D>		@		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan CMFD
>A>	AP			80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan CMFD
>D>		@		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan CMFD
>A>	AP			160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan CMFD

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

>A>	AB		MSN	0.125MG	A213220	001	Jan 29, 2020	Jan NEWA
>A>	AB			0.25MG	A213220	002	Jan 29, 2020	Jan NEWA
>A>	AB			0.5MG	A213220	003	Jan 29, 2020	Jan NEWA

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

>D>	AB		ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan DISC
>A>		@		EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan DISC
>D>	AB			EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan DISC
>A>		@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan DISC
>D>	AB			EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan DISC
>A>		@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan DISC
>D>	AB			EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan DISC
>A>		@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan DISC

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>A>	AP		NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>D>	AB		MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan DISC
>A>		@		EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan DISC

DRONABINOL

CAPSULE;ORAL

DRONABINOL

>A>	AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan NEWA
>A>	AB			5MG	A207421	002	Feb 07, 2020	Jan NEWA
>A>	AB			10MG	A207421	003	Feb 07, 2020	Jan NEWA

MARINOL

>D>	AB	+	ABBVIE	2.5MG	N018651	001	May 31, 1985	Jan CAHN
>D>	AB	+!		5MG	N018651	002	May 31, 1985	Jan CAHN
>D>	AB	+		10MG	N018651	003	May 31, 1985	Jan CAHN
>A>	AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan CAHN
>A>	AB	+!		5MG	N018651	002	May 31, 1985	Jan CAHN

CAPSULE;ORAL
MARINOL

>A> AB	+		10MG	N018651	003	May 31, 1985	Jan CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL

>A> AB		ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan CAHN
>D> AB		ANDA REPOSITORY	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan CAHN

TABLET;ORAL-28
DROSPIRENONE AND ETHINYL ESTRADIOL

>A> AB		HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan NEWA

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

>D> AB		ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan DISC
>A>	@		0.5MG	A202808	001	Nov 20, 2015	Jan DISC

>A> EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE;ORAL
>A> TRIJARDY XR

>A>	+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan NEWA
>A>	+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan NEWA
>A>	+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan NEWA
>A>	+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan NEWA

ENTECAVIR

TABLET;ORAL
ENTECAVIR

>D> AB		MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan DISC
>A>	@		0.5MG	A206226	001	Mar 26, 2019	Jan DISC
>D> AB			1MG	A206226	002	Mar 26, 2019	Jan DISC
>A>	@		1MG	A206226	002	Mar 26, 2019	Jan DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL
ESCITALOPRAM OXALATE

>D> AA		ALLIED	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan CAHN
>A> AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

>D> AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Jan DISC
>A>	@		0.5MG;0.1MG	A200747	001	Mar 08, 2012	Jan DISC

ESTROPIPATE

TABLET;ORAL
>D> ESTROPIPATE

>D>		MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan DISC
>A>	@		0.75MG	A040359	001	Aug 26, 1999	Jan DISC
>D>			1.5MG	A040359	002	Aug 26, 1999	Jan DISC
>A>	@		1.5MG	A040359	002	Aug 26, 1999	Jan DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
BALCOLTRA

>D>		AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CRLD
>A>	+!		0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CHRS
>A>	+		0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
LOESTRIN 24 FE

>D> AB	+	APIL	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan CAHN
>A> AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan CAHN

TABLET;ORAL-21
LOESTRIN 21 1.5/30

>D> AB	+	APIL	0.03MG;1.5MG	N017875	001		Jan CAHN
>A> AB	+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jan CAHN

TABLET;ORAL-21
LOESTRIN 21 1/20

>D>	AB	+	APIL	0.02MG;1MG	N017876	001		Jan CAHN
>A>	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jan CAHN

LOESTRIN FE 1.5/30

>D>	AB	+!	APIL	0.03MG;1.5MG	N017355	001		Jan CAHN
>A>	AB	+!	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jan CAHN

TABLET;ORAL-28
LOESTRIN FE 1/20

>D>	AB	+	APIL	0.02MG;1MG	N017354	001		Jan CAHN
>A>	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jan CAHN

EXEMESTANE

TABLET;ORAL
EXEMESTANE

>D>	AB		MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jan DISC
>A>		@		25MG	A208764	001	Aug 08, 2019	Jan DISC

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE

>D>	AB		AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan CHRS
>A>	AB	!		40MG	A206530	002	Dec 22, 2015	Jan CHRS
>D>			PEPCID					
>D>	AB	+	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan DISC
>A>		+ @		20MG	N019462	001	Oct 15, 1986	Jan DISC
>D>	AB	+!		40MG	N019462	002	Oct 15, 1986	Jan DISC
>A>		+ @		40MG	N019462	002	Oct 15, 1986	Jan DISC

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

>D>	AB		AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018	Jan CAHN
>D>	AB			134MG	A209504	002	Apr 30, 2018	Jan CAHN
>D>	AB			200MG	A209504	003	Apr 30, 2018	Jan CAHN
>A>	AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan CAHN
>A>	AB			134MG	A209504	002	Apr 30, 2018	Jan CAHN
>A>	AB			200MG	A209504	003	Apr 30, 2018	Jan CAHN

TABLET;ORAL
FENOFIBRATE

>A>	AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan NEWA
>A>	AB			160MG	A213252	002	Jan 17, 2020	Jan NEWA
>A>	AB		APPCO	54MG	A210670	001	Sep 06, 2019	Jan CAHN
>A>	AB			160MG	A210670	002	Sep 06, 2019	Jan CAHN
>D>		@	GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Jan CMFD
>A>	AB			54MG	A210606	001	Aug 17, 2018	Jan CMFD
>D>		@		160MG	A210606	002	Aug 17, 2018	Jan CMFD
>A>	AB			160MG	A210606	002	Aug 17, 2018	Jan CMFD
>D>	AB		NUVO PHARM	54MG	A210670	001	Sep 06, 2019	Jan CAHN
>D>	AB			160MG	A210670	002	Sep 06, 2019	Jan CAHN

>A> FERRIC DERISOMALTOSE

>A> SOLUTION;INTRAVENOUS
>A> MONOFERRIC

>A>		+!	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan NEWA
>A>		+!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan NEWA
>A>		+!		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA

FIDAXOMICIN

>A> FOR SUSPENSION;ORAL
>A> DIFICID

>A>		+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020	Jan NEWA

FLUCONAZOLE

TABLET;ORAL
FLUCONAZOLE

>D>	AB		MYLAN	50MG	A076351	001	Jul 29, 2004	Jan DISC
>A>		@		50MG	A076351	001	Jul 29, 2004	Jan DISC
>D>	AB			100MG	A076351	002	Jul 29, 2004	Jan DISC
>A>		@		100MG	A076351	002	Jul 29, 2004	Jan DISC
>D>	AB			150MG	A076351	003	Jul 29, 2004	Jan DISC
>A>		@		150MG	A076351	003	Jul 29, 2004	Jan DISC

TABLET;ORAL
FLUCONAZOLE

>D> AB		200MG	A076351	004	Jul 29, 2004	Jan DISC
>A>	@	200MG	A076351	004	Jul 29, 2004	Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>A> AP	UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020	Jan NEWA

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

>A> AB	ZYDUS PHARMS	0.1%	A208989	001	Feb 10, 2020	Jan NEWA

FOLIC ACID

INJECTABLE;INJECTION
FOLIC ACID

>D> AP	EXELA PHARMA SCS LLC	5MG/ML	A202522	001	Nov 06, 2019	Jan CAHN
>A> AP	X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan CAHN

FULVESTRANT

INJECTABLE;INTRAMUSCULAR
FULVESTRANT

>A> AO	CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Jan NEWA

FUROSEMIDE

TABLET;ORAL
FUROSEMIDE

>D> AB	AVET	20MG	N018413	001	Nov 30, 1983	Jan DISC
>A>	@	20MG	N018413	001	Nov 30, 1983	Jan DISC
>D> AB		40MG	N018413	002	Nov 30, 1983	Jan DISC
>A>	@	40MG	N018413	002	Nov 30, 1983	Jan DISC

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

>D>	@ CSPC OUYI	100MG	A075477	001	Mar 23, 2005	Jan CMFD
>A> AB		100MG	A075477	001	Mar 23, 2005	Jan CMFD
>D>	@	300MG	A075477	002	Mar 23, 2005	Jan CMFD
>A> AB		300MG	A075477	002	Mar 23, 2005	Jan CMFD
>D>	@	400MG	A075477	003	Mar 23, 2005	Jan CMFD
>A> AB		400MG	A075477	003	Mar 23, 2005	Jan CMFD

TABLET;ORAL
GRALISE

>A> BX	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CAHN
>A> BX	+!	600MG	N022544	002	Jan 28, 2011	Jan CAHN
>D> BX	+! ASSERTIO	300MG	N022544	001	Jan 28, 2011	Jan CAHN
>D> BX	+!	600MG	N022544	002	Jan 28, 2011	Jan CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

>D>	@ SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan CMFD
>A> AP		EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan CMFD
>D>	@	EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan CMFD
>A> AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan CMFD

GLYBURIDE

TABLET;ORAL
GLYBURIDE (MICRONIZED)

>D> AB	MYLAN	1.5MG	A074792	001	Jun 26, 1998	Jan DISC
>A>	@	1.5MG	A074792	001	Jun 26, 1998	Jan DISC
>D> AB		3MG	A074792	002	Jun 26, 1998	Jan DISC
>A>	@	3MG	A074792	002	Jun 26, 1998	Jan DISC
>D> AB		6MG	A074792	003	Aug 17, 1999	Jan DISC
>A>	@	6MG	A074792	003	Aug 17, 1999	Jan DISC

GRANISETRON HYDROCHLORIDE

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

>D>	AB		MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan DISC
>A>		@		EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>D>	AA		NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Jan CHRS
>A>	AA	!		1.5MG;5MG	A091528	001	Apr 20, 2011	Jan CHRS
>D>			TUSSIGON					
>D>	AA	!	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Jan DISC
>A>		@		1.5MG;5MG	A088508	001	Jul 30, 1985	Jan DISC

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA		STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Jan DISC
>A>		@		10MG	A200770	004	Jun 25, 2019	Jan DISC

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>D>	AB		MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan DISC
>A>		@		25MG	A040735	002	Jan 23, 2007	Jan DISC
>D>	AB			50MG	A040735	003	Jan 23, 2007	Jan DISC
>A>		@		50MG	A040735	003	Jan 23, 2007	Jan DISC

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

>A>								
>A>	AB		ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan NFTG
>A>	AB			15MG	A206986	002	Jan 21, 2020	Jan NFTG
>A>	AB			20MG	A206986	003	Jan 21, 2020	Jan NFTG
>A>	AB			30MG	A206986	004	Jan 21, 2020	Jan NFTG
>A>	AB			40MG	A206986	005	Jan 21, 2020	Jan NFTG
>A>	AB			50MG	A206986	006	Jan 21, 2020	Jan NFTG

ZOHYDRO ER

>D>		+!	PERSION	10MG	N202880	001	Oct 25, 2013	Jan CFTG
>A>	AB	+!		10MG	N202880	001	Oct 25, 2013	Jan CFTG
>D>		+		15MG	N202880	002	Oct 25, 2013	Jan CFTG
>A>	AB	+		15MG	N202880	002	Oct 25, 2013	Jan CFTG
>D>		+		20MG	N202880	003	Oct 25, 2013	Jan CFTG
>A>	AB	+		20MG	N202880	003	Oct 25, 2013	Jan CFTG
>D>		+		30MG	N202880	004	Oct 25, 2013	Jan CFTG
>A>	AB	+		30MG	N202880	004	Oct 25, 2013	Jan CFTG
>D>		+		40MG	N202880	005	Oct 25, 2013	Jan CFTG
>A>	AB	+		40MG	N202880	005	Oct 25, 2013	Jan CFTG
>D>		+		50MG	N202880	006	Oct 25, 2013	Jan CFTG
>A>	AB	+		50MG	N202880	006	Oct 25, 2013	Jan CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

>A>		+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Jan NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERON CAPROATE

>D>	AP1		AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan CMS1

HYDROXYPROGESTERONE CAPROATE

>A>	AP1		AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan CMS1

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>D>	AB		AMERIGEN PHARMS LTD	1.25MG	A075201	001	Dec 04, 1998	Jan CAHN
>D>	AB			2.5MG	A075201	002	Dec 04, 1998	Jan CAHN
>A>	AB		ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan CAHN
>A>	AB			2.5MG	A075201	002	Dec 04, 1998	Jan CAHN

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

>A>	AB	HERITAGE	25MG	N018851	001	May 18, 1984	Jan	CAHN
>A>	AB		50MG	N018851	002	May 18, 1984	Jan	CAHN
>D>	AB	HERITAGE PHARMS INC	25MG	N018851	001	May 18, 1984	Jan	CAHN
>D>	AB		50MG	N018851	002	May 18, 1984	Jan	CAHN

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG KWIKPEN

>D>	+!	LILLY	200UNITS/ML	N020563	004	Nov 15, 2019	Jan	CMS1
>A>	+!		200UNITS/ML	N020563	004	Jan 06, 2017	Jan	CMS1

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

>D>	@	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD
>A>	AB		0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

NORMODYNE

>D>	@	SCHERING	5MG/ML	N018686	001	Aug 01, 1984	Jan	CRLD
>A>	+ @		5MG/ML	N018686	001	Aug 01, 1984	Jan	CRLD

>A> LASMIDITAN SUCCINATE

>A> TABLET;ORAL

>A> REYVOW

>A>	+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
>A>	+!		100MG	N211280	002	Jan 31, 2020	Jan	NEWA

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

>A>	AB	LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
>A>	AB		20MG	A211863	002	Feb 04, 2020	Jan	NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

THYRO-TABS

>D>	AB2, AB4	+! ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS
>A>	AB2, AB4	+	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

>D>	@	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
>A>	AB		EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
>D>	@		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
>A>	AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
>D>	@		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD
>A>	AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

>D>	AB	+ HIKMA	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
>A>	AB	+	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
>D>	AB	+	300MG	N017812	001		Jan	CAHN
>A>	AB	+	300MG	N017812	001		Jan	CAHN
>D>	AB	+!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
>A>	AB	+!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
>D>	AB	MYLAN	150MG	A076243	002	Feb 24, 2003	Jan	DISC
>A>	@		150MG	A076243	002	Feb 24, 2003	Jan	DISC
>D>	AB		300MG	A076243	001	Jun 27, 2002	Jan	DISC
>A>	@		300MG	A076243	001	Jun 27, 2002	Jan	DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

>D>	AA	+!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
>A>	AA	+!		EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN

MAZINDOL

TABLET;ORAL

SANOREX

>D>		+ @	HEXIM	1MG	N017247	001		Jan CAHN
>D>		+ @		2MG	N017247	002		Jan CAHN
>A>		+ @	NOVARTIS	1MG	N017247	001		Jan CAHN
>A>		+ @		2MG	N017247	002		Jan CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D>	AA		MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan DISC
>A>		@		12.5MG	A202640	001	Sep 17, 2012	Jan DISC
>D>	AA			25MG	A202640	002	Sep 17, 2012	Jan DISC
>A>		@		25MG	A202640	002	Sep 17, 2012	Jan DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

>D>	AP		NORATECH	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan DISC
>A>		@	TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan DISC

MESALAMINE

SUPPOSITORY;RECTAL

MESALAMINE

>A>	AB		ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

>A>		+!	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN
>D>		+!	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>D>	AB		MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
>A>		@		500MG	A075976	001	Jan 24, 2002	Jan DISC
>D>	AB			850MG	A075976	002	Jan 24, 2002	Jan DISC
>A>		@		850MG	A075976	002	Jan 24, 2002	Jan DISC
>D>	AB			1GM	A075976	003	Jan 24, 2002	Jan DISC
>A>		@		1GM	A075976	003	Jan 24, 2002	Jan DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

>D>	AP		MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Jan DISC
>A>		@		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Jan DISC
>D>	AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Jan DISC
>A>		@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Jan DISC
>D>	AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Jan DISC
>A>		@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Jan DISC
>D>	AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Jan CTEC
>A>				EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Jan CTEC

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB		ACCORD HLTHCARE	EQ 2.5MG BASE	A213343	001	Jan 24, 2020	Jan NEWA
>A>	AB		EUGIA PHARMA	EQ 2.5MG BASE	A210454	001	Jan 30, 2020	Jan NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>D>	AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC
>A>		@	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC
>D>	AB		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan DISC
>A>		@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan DISC
>D>	AB		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan DISC
>A>		@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan DISC

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

>A>	AB	YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan NEWA
>A>	AB		50MG	A208955	002	Feb 05, 2020	Jan NEWA
>A>	AB		100MG	A208955	003	Feb 05, 2020	Jan NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan DISC
>A>		@	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan DISC
>D>	AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan DISC
>A>		@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan DISC

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

>D>		MIRABEGRON					
>D>	AB	SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan DISC
>A>		@	25MG	A209446	001	Dec 27, 2019	Jan DISC
		MYRBETRIQ					
>D>	AB	+! APGDI	25MG	N202611	001	Jun 28, 2012	Jan CTEC
>A>		+!	25MG	N202611	001	Jun 28, 2012	Jan CTEC

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>D>	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan DISC
>A>		@	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan DISC
>D>	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan DISC
>A>		@	EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan DISC

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

>A>	AP	PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jan NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

>D>	AB	MYLAN	250MG	A074121	001	Dec 21, 1993	Jan DISC
>A>		@	250MG	A074121	001	Dec 21, 1993	Jan DISC
>D>	AB		375MG	A074121	002	Dec 21, 1993	Jan DISC
>A>		@	375MG	A074121	002	Dec 21, 1993	Jan DISC
>D>	AB		500MG	A074121	003	Dec 21, 1993	Jan DISC
>A>		@	500MG	A074121	003	Dec 21, 1993	Jan DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>D>	AB	MYLAN	500MG	A203742	001	Feb 22, 2019	Jan DISC
>A>		@	500MG	A203742	001	Feb 22, 2019	Jan DISC
>D>	AB		750MG	A203742	002	Feb 22, 2019	Jan DISC
>A>		@	750MG	A203742	002	Feb 22, 2019	Jan DISC
>D>	AB		1GM	A203742	003	Feb 22, 2019	Jan DISC
>A>		@	1GM	A203742	003	Feb 22, 2019	Jan DISC

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

>A>		+!	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan CAHN
>D>		+!	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan CAHN

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

>D>	AB1	+!	APIL	0.35MG	N017060	001		Jan CAHN
>A>	AB1	+!	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan CAHN

OCTREOTIDE ACETATE

>A> SOLUTION;SUBCUTANEOUS

>A> BYNFEZIA PEN

>A>		+!	SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>D>	AB		TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan DISC
>A>		@		2.5MG	A076000	001	Oct 24, 2011	Jan DISC
>D>	AB			5MG	A076000	002	Oct 24, 2011	Jan DISC
>A>		@		5MG	A076000	002	Oct 24, 2011	Jan DISC
>D>	AB			7.5MG	A076000	003	Oct 24, 2011	Jan DISC
>A>		@		7.5MG	A076000	003	Oct 24, 2011	Jan DISC
>D>	AB			10MG	A076000	004	Oct 24, 2011	Jan DISC
>A>		@		10MG	A076000	004	Oct 24, 2011	Jan DISC
>D>	AB			15MG	A076000	005	Oct 24, 2011	Jan DISC
>A>		@		15MG	A076000	005	Oct 24, 2011	Jan DISC

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

>A>	AB		AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

>D>	AB		MYLAN	20MG	A075876	002	May 29, 2003	Jan DISC
>A>		@		20MG	A075876	002	May 29, 2003	Jan DISC

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AB		MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan DISC
>A>		@		EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan DISC
>D>	AB			EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan DISC
>A>		@		EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan DISC

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

>D>	AB		MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan DISC
>A>		@		10MG	A076644	001	Nov 09, 2006	Jan DISC
>D>	AB			15MG	A076644	002	May 10, 2007	Jan DISC
>A>		@		15MG	A076644	002	May 10, 2007	Jan DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>D>	AA		ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan DISC
>A>		@		100MG/5ML	A203447	001	Aug 30, 2017	Jan DISC
>A>	AA		AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan NEWA
>A>	AA			100MG/5ML	A212429	002	Jan 27, 2020	Jan NEWA

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan DISC
>A>	@		EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan DISC
>D>	AB		EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan DISC
>A>	@		EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan DISC
>D>	AB		EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan DISC
>A>	@		EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan DISC
>D>	AB		EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan DISC
>A>	@		EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan DISC

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

>D>		@ NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan CRLD
>A>	+	@	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan CRLD

PEGVISOMANT

INJECTABLE;SUBCUTANEOUS

SOMAVERT

>A>	+!	PHARMACIA	10MG/VIAL	N021106	001	Mar 25, 2003	Jan CAHN
>A>	+!		15MG/VIAL	N021106	002	Mar 25, 2003	Jan CAHN
>A>	+!		20MG/VIAL	N021106	003	Mar 25, 2003	Jan CAHN
>A>	+!		25MG/VIAL	N021106	004	Jul 31, 2014	Jan CAHN
>A>	+!		30MG/VIAL	N021106	005	Jul 31, 2014	Jan CAHN
>D>	+!	PHARMACIA AND UPJOHN	10MG/VIAL	N021106	001	Mar 25, 2003	Jan CAHN
>D>	+!		15MG/VIAL	N021106	002	Mar 25, 2003	Jan CAHN
>D>	+!		20MG/VIAL	N021106	003	Mar 25, 2003	Jan CAHN
>D>	+!		25MG/VIAL	N021106	004	Jul 31, 2014	Jan CAHN
>D>	+!		30MG/VIAL	N021106	005	Jul 31, 2014	Jan CAHN

PENICILLAMINE

CAPSULE;ORAL

PENICILLAMINE

>D>	AB	AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Jan CAHN
>A>	AB	ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>A>	AP1	RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan NEWA
>A>	AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan NEWA
>A>	AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
>A>	@		EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
>D>	AB		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
>A>	@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
>D>	AB		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC
>A>	@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC

PODOFILOX

SOLUTION;TOPICAL

CONDYLOX

>D>	AT	+! ALLERGAN	0.5%	N019795	001	Dec 13, 1990	Jan CAHN
>A>	AT	+! TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan CAHN

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

>D>		@ GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036	001		Jan CMS1
>A>		@	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan CMS1

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB		MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan DISC
>A>		@		0.125MG	A077854	001	Oct 08, 2010	Jan DISC
>D>	AB			0.25MG	A077854	002	Oct 08, 2010	Jan DISC
>A>		@		0.25MG	A077854	002	Oct 08, 2010	Jan DISC
>D>	AB			0.5MG	A077854	003	Oct 08, 2010	Jan DISC
>A>		@		0.5MG	A077854	003	Oct 08, 2010	Jan DISC
>D>	AB			0.75MG	A090764	001	Apr 09, 2010	Jan DISC
>A>		@		0.75MG	A090764	001	Apr 09, 2010	Jan DISC
>D>	AB			1MG	A077854	004	Oct 08, 2010	Jan DISC
>A>		@		1MG	A077854	004	Oct 08, 2010	Jan DISC
>D>	AB			1.5MG	A077854	005	Oct 08, 2010	Jan DISC
>A>		@		1.5MG	A077854	005	Oct 08, 2010	Jan DISC

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

>D>	AB		NOVARTIS	1%	N017469	001		Jan CRLD
>A>	AB	+!		1%	N017469	001		Jan CHRS
>A>	AB	+		1%	N017469	001		Jan CRLD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB		AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan DISC
>A>		@		EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan DISC
>D>	AB	!		EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan DISC
>A>		@		EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan DISC
>D>	AB		STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan DISC
>A>		@		EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan DISC
>D>	AB			EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan CHRS
>A>	AB	!		EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan CHRS
>D>	AB			EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan DISC
>A>		@		EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

>D>	AB		AMERIGEN PHARMS LTD	500MG	A210482	001	Oct 29, 2019	Jan CAHN
>D>	AB			1GM	A210482	002	Oct 29, 2019	Jan CAHN
>A>	AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan CAHN
>A>	AB			1GM	A210482	002	Oct 29, 2019	Jan CAHN
>A>	AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan NEWA
>A>	AB			1GM	A212284	002	Feb 12, 2020	Jan NEWA

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION

YUTOPAR

>D>		@	ASTRAZENECA	15MG/ML	N018580	002		Jan CMS1
>A>		@		15MG/ML	N018580	002	Sep 27, 1984	Jan CMS1

SELEXIPAG

TABLET;ORAL

UPTRAVI

>D>		+	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
>A>		+!		0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
>D>		+!		1.6MG	N207947	008	Dec 21, 2015	Jan CHRS
>A>		+		1.6MG	N207947	008	Dec 21, 2015	Jan CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

>A>		+!	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan NEWA

SODIUM IODIDE I-131

SOLUTION;ORAL

HICON

>D>		+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan CFTG
>A>	AA	+!		250-1000mCi	N021305	007	Dec 05, 2011	Jan CFTG

>A> SODIUM IODIDE I 131

>A>	AA		INTL ISOTOPES	250-1000mCi	A209166	001	Feb 05, 2020	Jan NFTG

SODIUM PHENYLBUTYRATE

TABLET;ORAL

SODIUM PHENYLBUTYRATE

>D>	AB		ALVOGEN	500MG	A090910	001	Nov 18, 2011	Jan DISC
>A>		@		500MG	A090910	001	Nov 18, 2011	Jan DISC

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

>D>		+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jan CAIN
>D>		+		150MG	N211230	002	Jun 17, 2019	Jan CAIN

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

>A>		+	JAZZ	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jan CPOT
>A>		+		75MG	N211230	001	Jun 17, 2019	Jan CAIN
>A>		+		EQ 150MG BASE	N211230	002	Jun 17, 2019	Jan CPOT
>A>		+		150MG	N211230	002	Jun 17, 2019	Jan CAIN

>A> SOMATROPIN

>A> INJECTABLE;INJECTION

>A> ACCRETROPIN

>A>		@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Jan CAIN

>A> HUMATROPE

>A>		@	LILLY	2MG/VIAL	N019640	001	Jun 23, 1987	Jan CAIN
>A>	BX	+!		5MG/VIAL	N019640	004	Mar 08, 1987	Jan CAIN
>A>	BX	+		6MG/VIAL	N019640	005	Feb 04, 1999	Jan CAIN
>A>		+!		12MG/VIAL	N019640	006	Feb 04, 1999	Jan CAIN
>A>		+!		24MG/VIAL	N019640	007	Feb 04, 1999	Jan CAIN

>D> SOMATROPIN RECOMBINANT

>D> INJECTABLE;INJECTION

>D> ACCRETROPIN

>D>		@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Jan CAIN

>D> HUMATROPE

>D>		@	LILLY	2MG/VIAL	N019640	001	Jun 23, 1987	Jan CAIN
>D>	BX	+!		5MG/VIAL	N019640	004	Mar 08, 1987	Jan CAIN
>D>	BX	+		6MG/VIAL	N019640	005	Feb 04, 1999	Jan CAIN
>D>		+!		12MG/VIAL	N019640	006	Feb 04, 1999	Jan CAIN
>D>		+!		24MG/VIAL	N019640	007	Feb 04, 1999	Jan CAIN

>A> TAZEMETOSTAT HYDROBROMIDE

>A> TABLET;ORAL

>A> TAZVERIK

>A>		+!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	Jan NEWA

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

>A>	AP		SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Jan NEWA

TELMISARTAN

TABLET;ORAL

TELMISARTAN

>D>	AB		JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Jan DISC
>A>		@		20MG	A204164	001	Aug 22, 2016	Jan DISC
>D>	AB			40MG	A204164	002	Aug 22, 2016	Jan DISC
>A>		@		40MG	A204164	002	Aug 22, 2016	Jan DISC
>D>	AB			80MG	A204164	003	Aug 22, 2016	Jan DISC
>A>		@		80MG	A204164	003	Aug 22, 2016	Jan DISC

>A>	TERIPARATIDE						
>A>	INJECTABLE;SUBCUTANEOUS						
>A>	FORTEO						
>A>	+! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
>A>	@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN
>A>	SOLUTION;SUBCUTANEOUS						
>A>	BONSITY						
>A>	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
>A>	FORTEO						
>A>	+! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR
>A>	@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CDFR
	TERIPARATIDE RECOMBINANT HUMAN						
>D>	INJECTABLE;SUBCUTANEOUS						
>D>	FORTEO						
>D>	+! LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
>D>	@	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN
>D>	SOLUTION;SUBCUTANEOUS						
>D>	BONSITY						
>D>	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
	TETRABENAZINE						
	TABLET;ORAL						
	TETRABENAZINE						
>A> AB	PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan	NEWA
>A> AB		25MG	A213316	002	Jan 22, 2020	Jan	NEWA
	TOLTERODINE TARTRATE						
	TABLET;ORAL						
	TOLTERODINE TARTRATE						
>D> AB	MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012	Jan	DISC
>A>	@	1MG	A202641	001	Nov 27, 2012	Jan	DISC
>D> AB		2MG	A202641	002	Nov 27, 2012	Jan	DISC
>A>	@	2MG	A202641	002	Nov 27, 2012	Jan	DISC
>A> AB	UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020	Jan	NEWA
>A> AB		2MG	A204721	002	Jan 24, 2020	Jan	NEWA
	TRANEXAMIC ACID						
	INJECTABLE;INJECTION						
	TRANEXAMIC ACID						
>D> AP	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan	DISC
>A>	@	100MG/ML	A212360	001	Jul 17, 2019	Jan	DISC
	TABLET;ORAL						
	TRANEXAMIC ACID						
>D>	@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jan	CAHN
>A>	@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan	CAHN
	TRAZODONE HYDROCHLORIDE						
	TABLET;ORAL						
	TRAZODONE HYDROCHLORIDE						
>A> AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan	NEWA
>A> AB		100MG	A204852	002	Feb 05, 2020	Jan	NEWA
>A> AB		150MG	A204852	003	Feb 05, 2020	Jan	NEWA
>A> AB		300MG	A204852	004	Feb 05, 2020	Jan	NEWA
	TRIAZOLAM						
	TABLET;ORAL						
	TRIAZOLAM						
>D> AB	MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan	DISC
>A>	@	0.125MG	A074031	001	Mar 25, 1994	Jan	DISC
>D> AB		0.25MG	A074031	002	Mar 25, 1994	Jan	DISC
>A>	@	0.25MG	A074031	002	Mar 25, 1994	Jan	DISC
	URSODIOL						
	CAPSULE;ORAL						
	URSODIOL						
>A> AB	RISING	300MG	A213200	001	Feb 12, 2020	Jan	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

>D>	AB	TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan	DISC
>A>		@	EQ 500MG BASE	A077655	001	May 24, 2010	Jan	DISC
>D>	AB		EQ 1GM BASE	A077655	002	May 24, 2010	Jan	DISC
>A>		@	EQ 1GM BASE	A077655	002	May 24, 2010	Jan	DISC

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

>A>	AB	GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	AP	MUSTAFA NEVZAT ILAC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CAHN
>A>	AP	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Jan	CDFR

>A> SYRUP;ORAL

>A> CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Jan	CDFR

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>A>	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan	CMS1
>D>	MYLAN	10MG	A075674	001	Dec 21, 2001	Jan	DISC
>A>	@	10MG	A075674	001	Dec 21, 2001	Jan	DISC

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D>	AMNEAL PHARMS	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN
>D>	@ APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD
>A>		1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD
>A>	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN

LORATADINE

TABLET;ORAL

LORATADINE

>D>	MYLAN	10MG	A075790	001	Nov 07, 2008	Jan	DISC
>A>	@	10MG	A075790	001	Nov 07, 2008	Jan	DISC
>D>		10MG	A078447	001	Aug 12, 2011	Jan	DISC
>A>	@	10MG	A078447	001	Aug 12, 2011	Jan	DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

>D>	@ LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jan	CMFD
>A>		17GM/PACKET	A090600	001	Oct 06, 2009	Jan	CMFD
>D>	@	17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jan	CMFD
>A>		17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jan	CMFD

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 01 JANUARY 2020

NO JANUARY 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JANUARY 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN							
A 213115	001					>A> CGT	Jul 28, 2020
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	001	>A> 10525057	Mar 08, 2034	U-1632			
		>A> 10525057	Mar 08, 2034	U-2723			
		>A> 10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	002	>A> 10525057	Mar 08, 2034	U-1632			
		>A> 10525057	Mar 08, 2034	U-2723			
		>A> 10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	003	>A> 10525057	Mar 08, 2034	U-1632			
		>A> 10525057	Mar 08, 2034	U-2723			
		>A> 10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971	004	>A> 10525057	Mar 08, 2034	U-1632			
		>A> 10525057	Mar 08, 2034	U-2723			
		>A> 10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	001	>A> 10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	002	>A> 10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	003	>A> 10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	004	>A> 10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	005	>A> 10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202	006	>A> 10517507	Jun 13, 2032	DP			
AVAPRITINIB - AYVAKIT							
N 212608	001	>A> 9200002	Oct 15, 2034	DS DP U-2726		>A> NCE	Jan 09, 2025
		>A> 9944651	Oct 15, 2034	DS DP U-2726			
		>A> 9994575	Oct 15, 2034	DS DP U-2726			
AVAPRITINIB - AYVAKIT							
N 212608	002	>A> 9200002	Oct 15, 2034	DS DP U-2726		>A> NCE	Jan 09, 2025
		>A> 9944651	Oct 15, 2034	DS DP U-2726			
		>A> 9994575	Oct 15, 2034	DS DP U-2726			
AVAPRITINIB - AYVAKIT							
N 212608	003	>A> 9200002	Oct 15, 2034	DS DP U-2726		>A> NCE	Jan 09, 2025
		>A> 9944651	Oct 15, 2034	DS DP U-2726			
		>A> 9994575	Oct 15, 2034	DS DP U-2726			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	>A> 7112592	Jan 07, 2026	DS DP U-2244			
		>A> 7112592	Jan 07, 2026	DS DP U-2508			
		>A> 7112592	Jan 07, 2026	DS DP U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	>A> 7112592	Jan 07, 2026	DS DP U-2244			
		>A> 7112592	Jan 07, 2026	DS DP U-2508			
		>A> 7112592	Jan 07, 2026	DS DP U-282			
BRILLIANT BLUE G - TISSUEBLUE							
N 209569	001					>A> NCE	Dec 20, 2024
						>A> ODE-282	Dec 20, 2026
CYSTEINE HYDROCHLORIDE - NOURESS							
N 212535	001	>A> 10493051	Mar 15, 2039	DP			
		>A> 10543186	Mar 15, 2039	U-2722			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	001	>A> 8329159	Jul 24, 2029	DS			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002	>A> 8329159	Jul 24, 2029	DS			
DEFERIPRONE - FERRIPROX							
N 021825	002	>A> 7049328	Jun 28, 2021	U-735			
DEOXYCHOLIC ACID - KYBELLA							
N 206333	001	>A> 10500214	Mar 02, 2030	DP			
DEXAMETHASONE - HEMADY							
N 211379	001	>A> 10537585	Dec 18, 2037	DP			
DIAZEPAM - VALTOCO							
N 211635	001	>A> 10265402	May 11, 2025	DP		>A> NP	Jan 10, 2023
		>A> 8895546	Mar 27, 2029	DP		>A> ODE-279	Jan 10, 2027
		>A> 8927497	Jul 21, 2025	DP U-2727			
		>A> 9642913	May 11, 2025	DP			
		>A> 9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO							
N 211635	002	>A> 10265402	May 11, 2025	DP		>A> NP	Jan 10, 2023
		>A> 8895546	Mar 27, 2029	DP		>A> ODE-279	Jan 10, 2027
		>A> 8927497	Jul 21, 2025	DP U-2727			
		>A> 9642913	May 11, 2025	DP			
		>A> 9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO							
N 211635	003	>A> 10265402	May 11, 2025	DP		>A> NP	Jan 10, 2023
		>A> 8895546	Mar 27, 2029	DP		>A> ODE-279	Jan 10, 2027
		>A> 8927497	Jul 21, 2025	DP U-2727			
		>A> 9642913	May 11, 2025	DP			
		>A> 9763876	Mar 27, 2029	DP U-2727			
EFINACONAZOLE - JUBLIA							
N 203567	001	>A> 10342875	Oct 02, 2034	DP U-2720			
		>A> 10478601	Apr 25, 2035	DP U-2721			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	001					>A> NPP	Sep 25, 2020
						>A> ODE-284	Sep 28, 2024
						>A> ODE-285	Sep 28, 2024
ENZALUTAMIDE - XTANDI							
N 203415	001	>A> 8183274	Aug 24, 2026	U-1281			
		>A> 8183274	Aug 24, 2026	U-1588			
		>A> 8183274	Aug 24, 2026	U-2345			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENZALUTAMIDE - XTANDI						
N 203415 001	>A> 8183274	Aug 24, 2026	U-2708			
	>A> 9126941	May 15, 2026	U-1588			
	>A> 9126941	May 15, 2026	U-2345			
	>A> 9126941	May 15, 2026	U-2708			
EPINEPHRINE - ADRENACLICK						
N 020800 003	>A> 10166334	Jan 21, 2025	DP			
EPINEPHRINE - ADRENACLICK						
N 020800 004	>A> 10166334	Jan 21, 2025	DP			
ETEPLIRSEN - EXONDYS 51						
N 206488 001	>A> 10533174	May 04, 2021	DP			
ETEPLIRSEN - EXONDYS 51						
N 206488 002	>A> 10533174	May 04, 2021	DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	>A> 10519252	Oct 20, 2023	DS U-2709			
	>A> 10519252	Oct 20, 2023	DS U-2710			
	>A> 10519252	Oct 20, 2023	DS U-2711			
	>A> 10519252	Oct 20, 2023	DS U-2712			
FERRIC CITRATE - AURYXIA						
N 205874 001	>A> 5753706	Feb 03, 2021	DP U-1577			
FIDAXOMICIN - DIFICID						
N 201699 001					>A> NPP	Jan 24, 2023
					>A> PED	Jul 24, 2023
FIDAXOMICIN - DIFICID						
N 213138 001					>A> NP	Jan 24, 2023
					>A> PED	Jul 24, 2023
FINGOLIMOD HYDROCHLORIDE - GILENYA						
N 022527 001	>A> 10543179	Dec 25, 2027	U-2719			
GLATIRAMER ACETATE - COPAXONE						
N 020622 003	>A> 8232250	Aug 19, 2030	U-441	Y		
	>A> 8399413	Aug 19, 2030	U-441	Y		
	>A> 8969302	Aug 19, 2030	U-441	Y		
	>A> 9155776	Aug 19, 2030	U-441	Y		
	>A> 9402874	Aug 19, 2030	U-441	Y		
GOLODIRSEN - VYONDYS 53						
N 211970 001	>A> 10533174	May 04, 2021	DP		>A> ODE-280	Dec 12, 2026
HYDROGEN PEROXIDE - ESKATA						
N 209305 001	>A> 10493103	Apr 21, 2035	DP			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001					>A> NCE	Jan 31, 2025
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002					>A> NCE	Jan 31, 2025
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	>A> 10464938	Mar 12, 2028	DP		>A> NCE	Dec 20, 2024
	>A> 7183282	Jun 15, 2020	DS DP			
	>A> 8598119	Dec 28, 2029	U-543			
	>A> 8648077	Dec 01, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500	001	>A> 9199995	Mar 12, 2029	U-2713			
		>A> 9586960	Mar 12, 2029	DS DP			
		>A> 9616061	May 27, 2029	DP			
		>A> 9956227	Dec 03, 2034	U-2714			
		>A> RE39680	Jun 15, 2020	DS DP U-543			
MICAFUNGIN SODIUM - MYCAMINE							
N 021506	002					>A> I-821	Dec 20, 2022
						>A> PED	Jun 20, 2023
MICAFUNGIN SODIUM - MYCAMINE							
N 021506	003					>A> I-821	Dec 20, 2022
						>A> PED	Jun 20, 2023
MIGALASTAT HYDROCHLORIDE - GALAFOLD							
N 208623	001	>A> 10525045	Apr 28, 2028	U-2371			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ							
N 212379	001	>A> 10517882	Oct 01, 2030	U-2647			
OCTREOTIDE ACETATE - BYNFEZIA PEN							
N 213224	001	>A> 10342850	May 15, 2038	DP			
OLAPARIB - LYNPARZA							
N 208558	001	>A> 8143241	Aug 12, 2027	U-2101		>A> ODE-283	Dec 27, 2026
		>A> 8143241	Aug 12, 2027	U-2103			
		>A> 8143241	Aug 12, 2027	U-2480			
		>A> 8143241	Aug 12, 2027	U-2481			
		>A> 8143241	Aug 12, 2027	U-2482			
		>A> 8143241	Aug 12, 2027	U-2483			
		>A> 8143241	Aug 12, 2027	U-2716			
		>A> 8859562	Aug 04, 2031	U-2101			
		>A> 8859562	Aug 04, 2031	U-2480			
		>A> 8859562	Aug 04, 2031	U-2481			
		>A> 8859562	Aug 04, 2031	U-2482			
		>A> 8859562	Aug 04, 2031	U-2483			
		>A> 8859562	Aug 04, 2031	U-2716			
		>A> 9566276	Mar 12, 2024	U-2716			
OLAPARIB - LYNPARZA							
N 208558	002	>A> 8143241	Aug 12, 2027	U-2101		>A> ODE-283	Dec 27, 2026
		>A> 8143241	Aug 12, 2027	U-2103			
		>A> 8143241	Aug 12, 2027	U-2480			
		>A> 8143241	Aug 12, 2027	U-2481			
		>A> 8143241	Aug 12, 2027	U-2482			
		>A> 8143241	Aug 12, 2027	U-2483			
		>A> 8143241	Aug 12, 2027	U-2716			
		>A> 8859562	Aug 04, 2031	U-2101			
		>A> 8859562	Aug 04, 2031	U-2480			
		>A> 8859562	Aug 04, 2031	U-2481			
		>A> 8859562	Aug 04, 2031	U-2482			
		>A> 8859562	Aug 04, 2031	U-2483			
		>A> 8859562	Aug 04, 2031	U-2716			
		>A> 9566276	Mar 12, 2024	U-2716			
OSELTAMIVIR PHOSPHATE - TAMIFLU							
N 021087	001					>A> M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU							
N 021087	002					>A> M-251	Aug 02, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 003					>A> M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 001					>A> M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 002					>A> M-251	Aug 02, 2022
PEMETREXED - PEMFEXY						
N 209472 001	>A> 7772209	May 24, 2022	U-2728			
	>A> 7772209	May 24, 2022	U-2729			
REVEFENACIN - YUPELRI						
N 210598 001	>A> 10550081	Jul 14, 2030	DS			
SELINEXOR - XPOVIO						
N 212306 001	>A> 10519139	Aug 14, 2035	DS DP U-2584			
SEMAGLUTIDE - OZEMPIC						
N 209637 001					>A> I-822	Jan 16, 2023
SEMAGLUTIDE - OZEMPIC						
N 209637 002					>A> I-822	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS						
N 213051 001					>A> M-252	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS						
N 213051 002					>A> M-252	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS						
N 213051 003					>A> M-252	Jan 16, 2023
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	>A> 10512609	Sep 05, 2037	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	>A> 10512609	Sep 05, 2037	U-2548			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH						
N 208223 001	>A> 10537554	Jan 29, 2036	U-72			
SUVOREXANT - BELSOMRA						
N 204569 001					>A> M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA						
N 204569 002					>A> M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA						
N 204569 003					>A> M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA						
N 204569 004					>A> M-253	Jan 29, 2023
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001					>A> NCE	Jan 23, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	001	>A> 8747897	Aug 11, 2031	DP		U-2724	
		>A> 8747897	Aug 11, 2031	DP		U-2725	
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	002	>A> 8747897	Aug 11, 2031	DP		U-2724	
		>A> 8747897	Aug 11, 2031	DP		U-2725	
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	003	>A> 8747897	Aug 11, 2031	DP		U-2724	
		>A> 8747897	Aug 11, 2031	DP		U-2725	
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	004	>A> 8747897	Aug 11, 2031	DP		U-2724	
		>A> 8747897	Aug 11, 2031	DP		U-2725	
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	>A> 8747897	Aug 11, 2031	DP		U-2724	
		>A> 8747897	Aug 11, 2031	DP		U-2725	
TRIPTORELIN PAMOATE - TRIPTODUR KIT							
N 208956	001	>A> 10166181	Jun 30, 2029	DP			
UBROGEPANT - UBRELVY							
N 211765	001	>A> 10117836	Jan 30, 2035	DP			
		>A> 8754096	Jul 19, 2032	DS DP		U-2717	
		>A> 8912210	Nov 10, 2031	DS DP			
		>A> 9499545	Nov 10, 2031	DS DP		U-2718	
		>A> 9833448	Nov 10, 2031			U-2718	
UBROGEPANT - UBRELVY							
N 211765	002	>A> 10117836	Jan 30, 2035	DP			
		>A> 8754096	Jul 19, 2032	DS DP		U-2717	
		>A> 8912210	Nov 10, 2031	DS DP			
		>A> 9499545	Nov 10, 2031	DS DP		U-2718	
		>A> 9833448	Nov 10, 2031			U-2718	
UPADACITINIB - RINVOQ							
N 211675	001	>A> 10519164	Oct 17, 2036	DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	001	>A> 7834020	Jun 05, 2022	DS DP		U-839	
		>A> 7834020*PED	Dec 05, 2022				
		>A> 8193195	Jun 05, 2022			U-839	
		>A> 8193195*PED	Dec 05, 2022				
		>A> 8236804	Jun 05, 2022			U-839	
		>A> 8236804*PED	Dec 05, 2022				
		>A> 8673921	Jun 05, 2022	DS DP			
		>A> 8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	002	>A> 7834020	Jun 05, 2022	DS DP		U-839	
		>A> 7834020*PED	Dec 05, 2022				
		>A> 8193195	Jun 05, 2022			U-839	
		>A> 8193195*PED	Dec 05, 2022				
		>A> 8236804	Jun 05, 2022			U-839	
		>A> 8236804*PED	Dec 05, 2022				
		>A> 8673921	Jun 05, 2022	DS DP			
		>A> 8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	003	>A> 7834020	Jun 05, 2022	DS DP		U-839	
		>A> 7834020*PED	Dec 05, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2020

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILAZODONE HYDROCHLORIDE - VIIBRYD								
N 022567	003	>A>	8193195	Jun 05, 2022	U-839			
		>A>	8193195*PED	Dec 05, 2022				
		>A>	8236804	Jun 05, 2022	U-839			
		>A>	8236804*PED	Dec 05, 2022				
		>A>	8673921	Jun 05, 2022	DS DP			
		>A>	8673921*PED	Dec 05, 2022				
VOXELOTOR - OXBRYTA								
N 213137	001	>A>	10017491	Dec 28, 2032	DP		>A> ODE-281	Nov 25, 2026
		>A>	10034879	Dec 28, 2032	DS DP			
		>A>	10493035	Oct 12, 2037	DP			
		>A>	9018210	Dec 28, 2032	DS DP			
		>A>	9248199	Jan 29, 2034	U-2676			
		>A>	9248199	Jan 29, 2034	U-2715			
		>A>	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm